Chrysin, a natural flavone, improves murine inflammatory bowel diseases

Biochemical and Biophysical Research Communications

Volumn 381, Issue 4, 2009, Pages 502-507

  Shin, Eun Kyung ^a   Kwon, Hyuck Se ^a   Kim, Yoon Hee ^a   Shin, Hyun Kyung ^a   Kim, Jin Kyung ^a  

^a Hallym University   (South Korea)

Author keywords

Chrysin; Inflammation; Inflammatory bowel disease; Inflammatory cytokines

Indexed keywords

CHRYSIN; CYTOKINE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; TISSUE LEVEL; TISSUE STRUCTURE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WEIGHT REDUCTION;

ANIMALS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FLAVONOIDS; I-KAPPA B PROTEINS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; PROTEIN TRANSPORT; WEIGHT LOSS;

MURINAE; MUS;

EID: 62649118631     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.02.071     Document Type: Article

References (38)

1. Scaldaferri F., and Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J. Dig. Dis. 8 (2007) 171-178
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
3. Hendrickson B.A., Gokhale R., and Cho J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 15 (2002) 79-94
4. Araki Y., Sugihara H., and Hattori T. The free radical scavengers edaravone and tempol suppress experimental dextran sulfate sodium-induced colitis in mice. Int. J. Mol. Med. 17 (2006) 331-334
5. Kolios G., Valatas V., and Ward S.G. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113 (2004) 427-437
6. Bonner G.F. Using COX-2 inhibitors in IBD: anti-inflammatories inflame a controversy. Am. J. Gastroenterol. 97 (2002) 783-785
7. Singer I.I., Kawka D.W., Schloemann S., Tessner T., Riehl T., and Stenson W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115 (1998) 297-306
8. Rojas-Cartagena C., Flores I., and Appleyard C.B. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine 32 (2005) 85-93
9. Kwon K.H., Murakami A., Hayashi R., and Ohigashi H. Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem. Biophys. Res. Commun. 337 (2005) 647-654
10. Mudter J., and Neurath M.F. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 13 (2007) 1016-1023
11. Brown S.J., and Mayer L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 109 (2007) 2058-2069
12. van Staa T.P., Card T., Logan R.F., and Leufkens H.G. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54 (2005) 1573-1578
13. Domènech E. Inflammatory bowel disease: current therapeutic options. Digestion 73 (2006) 67-76
14. Sandborn W.J., and Faubion W.A. Clinical pharmacology of inflammatory bowel disease therapies. Curr. Gastroenterol. Rep. 2 (2000) 440-445
15. Williams C.A., Harborne J.B., Newman M., Greenham J., and Eagles J. Chrysin and other leaf exudate flavonoids in the genus Pelargonium. Phytochemistry 46 (1997) 1349-1353
16. Rapta P., Misik V., Stasko A., and Vrabel I. Redox intermediates of flavonoids and caffeic acid esters from propolis: an EPR spectroscopy and cyclic voltammetry study. Free Radic. Biol. Med. 18 (1995) 901-908
17. Cho H., Yun C.W., Park W.K., Kong J.Y., Kim K.S., Park Y., Lee S., and Kim B.K. Modulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives. Pharmacol. Res. 49 (2004) 37-43
18. Koganov M.M., Dueva O.V., and Tsorin B.L. Activities of plant-derived phenols in a fibroblast cell culture model. J. Nat. Prod. 62 (1999) 481-483
19. Habtemariam S. Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells. J. Nat. Prod. 60 (1997) 775-778
20. Lapidot T., Walker M.D., and Kanner J. Antioxidant and prooxidant effects of phenolics on pancreatic beta-cells in vitro. J. Agric. Food Chem. 50 (2002) 7220-7225
21. Dhawan K., Kumar S., and Sharma A. Beneficial effects of chrysin and benzoflavone on virility in 2-year-old male rats. J. Med. Food 5 (2002) 43-48
22. Kwon H.S., Oh S.M., and Kim J.K. Glabridin, a functional compound of liquorice, attenuates colonic inflammation in mice with dextran sulphate sodium-induced colitis. Clin. Exp. Immunol. 151 (2008) 165-173
23. Krawisz J.E., Sharon P., and Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Gastroenterology 84 (1984) 1344-1345
24. Marrero J.A., Matkowskyj K.A., Yung K., Hecht G., and Benya R.V. Dextran sulfate sodium-induced murine colitis activates NF-kappaB and increases galanin-1 receptor expression. Am. J. Physiol. Gastrointest. Liver Physiol. 278 (2000) G797-G804
25. Yomogida S., Kojima Y., Tsutsumi-Ishii Y., Hua J., Sakamoto K., and Nagaoka I. Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats. Int. J. Mol. Med. 22 (2008) 317-323
26. Cooper H.S., Murthy S.N., Shah R.S., and Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69 (1993) 238-249
27. Ohtsuka Y., and Sanderson I.R. Dextran sulfate sodium-induced inflammation is enhanced by intestinal epithelial cell chemokine expression in mice. Pediatr. Res. 53 (2003) 143-147
28. Schottelius A.J., and Baldwin A.S. A role for transcription factor NF-kappa B in intestinal inflammation. Int. J. Colorectal Dis. 14 (1999) 18-28
29. Atreya I., Atreya R., and Neurath M.F. NF-kappaB in inflammatory bowel disease. J. Intern. Med. 263 (2008) 591-596
30. Spiik A.K., Ridderstad A., Axelsson L.G., Midtvedt T., Björk L., and Pettersson S. Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides. Int. J. Colorectal Dis. 17 (2002) 223-232
31. Fichtner-Feigl S., Fuss I.J., Preiss J.C., Strober W., and Kitani A. Treatment of murine Th1- and Th-2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J. Clin. Invest. 115 (2005) 3057-3071
32. Ghosh S., and Hayden M.S. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 8 (2008) 837-848
33. Suzuki K., Sugimura K., Hasegawa K., Yoshida K., Suzuki A., Ishizuka K., Ohtsuka K., Honma T., Narisawa R., and Asakura H. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand. J. Gastroenterol. 36 (2001) 1301-1306
34. Zhong W., Kolls J.K., Chen H., McAllister F., Oliver P.D., and Zhang Z. Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease. Front. Biosci. 13 (2008) 1654-1664
35. Lotito S.B., and Frei B. Dietary flavonoids attenuate tumor necrosis factor alpha-induced adhesion molecule expression in human aortic endothelial cells. Structure-function relationships and activity after first pass metabolism. Biol. Chem. 281 (2006) 37102-37110
36. Lin C.M., Chang H., Li S.Y., Wu I.H., and Chiu J.H. Chrysin inhibits lipopolysaccharide-induced angiogenesis via down-regulation of VEGF/VEGFR-2(KDR) and IL-6/IL-6R pathways. Planta. Med. 72 (2006) 708-714
37. 2 formation in RAW 264.7 cells. J. Nutr. 136 (2006) 1517-1521
38. Chen C.C., Chow M.P., Huang W.C., Lin Y.C., and Chang Y.J. Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: structure-activity relationships. Mol. Pharmacol. 66 (2004) 683-693